NCT00083525View on ClinicalTrials.gov

Urokinase-Plasminogen Activator (uPA) Inhibitor WX-UK1 in Combination With Capecitabine in Advanced Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

May 31, 2004

Conditions
Advanced Malignancies
Interventions
DRUG

WX-UK1 in combination with Capecitabine

Trial Locations (1)

19111

Fox Chase Cancer Center, Philadelphia

Sponsors
All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

Heidelberg Pharma AG

INDUSTRY